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Summary:
Ductal carcinoma in situ (DCIS) of the breast is a lesion characterized by significant
heterogeneity, in terms of morphology, immunohistochemical staining, molecular signatures and
clinical expression. For some patients, surgical excision provides adequate treatment, but a
subset of patients will experience recurrence of DCIS or progression to invasive ductal
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carcinoma (IDC). Recent years have seen extensive research aimed at identifying the molecular
events that characterize the transition from normal epithelium to DCIS and IDC. Tumor epithelial
cells, myoepithelial cells and stromal cells undergo alterations in gene expression, which are
most important in the early stages of breast carcinogenesis. Epigenetic modifications, such as
DNA methylation, together with microRNA (miRNA) alterations, play a major role in these
genetic events. Additionally, tumor proliferation and invasion is facilitated by the lesional
microenvironment, which includes stromal fibroblasts and macrophages that secrete growth
factors and angiogenesis-promoting substances. Characterization of DCIS on a molecular level
may better account for the heterogeneity of these lesions and how this manifests as differences
in patient outcome and response to therapy. Molecular assays originally developed for
assessing likelihood of recurrence in IDC are recently being applied to DCIS, with promising
results. In the future, the classification of DCIS will likely incorporate molecular findings along
with histologic and immunohistochemical features, allowing for personalized prognostic
information and therapeutic options for patients with DCIS. This review summarizes current data
regarding the molecular characterization of DCIS and discusses the potential clinical relevance.
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1. Introduction
DCIS accounts for approximately 20% of all newly diagnosed breast cancer cases in the United
States [1]. DCIS is defined as a neoplastic proliferation of epithelial cells with varying degrees of
cytological atypia that are confined to the mammary ductal-lobular system. DCIS itself does not
result in mortality, and breast cancer-specific mortality among women with DCIS is extremely
low with 1.0-2.6% dying from invasive breast cancer (IBC) 8-10 years after a diagnosis of DCIS
[2]. Due to the non-invasive nature and overall favorable prognosis of DCIS, a 2009 National
Institutes of Health State-of-the-Science Conference issued a statement which advocated
elimination of the term “carcinoma” in the name of this lesion [3]. Since DCIS is a non-obligate
precursor of invasive ductal carcinoma (IDC), an invasive component is found in a subset of
women who develop DCIS recurrence [4]. Furthermore, experimental data has shown that
carcinoma precursor cells exist in DCIS lesions, suggesting that the aggressive phenotype of
breast cancer is predetermined early at the pre-malignant stage [5].

Significant advances have been made in the diagnosis and therapy of patients with ductal
carcinoma in situ of the breast (DCIS). Early detection has led to an increase in DCIS cases
seen by pathologists in their daily practice. While a majority of women are treated by surgical
excision followed by radiation therapy and anti-hormonal medications, a number of series have
also demonstrated the natural course of untreated DCIS [4,6,7]. While data demonstrates that
there could be a population of patients who can safely undergo observation after a breastconserving surgery, many physicians and patients are reticent to undergo this course of
treatment for fear of recurrence [7,8]. Fifty percent of DCIS recurrence actually presents as an
invasive cancer; therefore, consequences could be significant [9]. Thus, it is likely that a
significant number of patients are being overtreated.
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However, considering potential long-term side effects of radiation therapy, it seems prudent to
identify a population of patients to observe without further therapy. Studies have shown that
certain clinical and pathological features of DCIS may be prognostic of local and/or invasive
recurrence following surgical excision [6,7,10]. For instance, many studies have suggested that
the tumor size is a strong predictor of local recurrence [7,11]. Nuclear grade and margin status
are other factors that appear to influence recurrence in DCIS, though certainly there are studies
that refute these findings [12]. Two major clinical tools that aid in risk stratification and
treatment planning--the University of Southern California/Van Nuys Prognostic Index and the
DCIS nomogram introduced by Rudloff et al.--utilize both clinical and pathologic factors such as
tumor size, necrosis, and margin status [10,13,14]. While our current ability to accurately
predict recurrence on the basis of this parameters is limited, clearly the paradigm that “one
approach fits all” in patients with DCIS is shifting. The current understanding is that DCIS is not
one disease but a heterogeneous group of cancers with distinct morphologic,
immunohistochemical, and biological features.

Recent research efforts have focused on classifying patients who may be managed
conservatively and those who are at higher risk for disease progression and may require
adjuvant therapy. The ideal classification scheme would be clinically useful and easy to adapt
with the ability to stratify patients into prognostic groups. While not consistently identified in all
studies, certain histopathological parameters such as lesion size, margin status, architectural
pattern, nuclear grade, presence of comedo necrosis, and expression of various
immunohistochemical markers have been variably shown to affect the risk of recurrence in premalignant breast lesions [12]. Improved molecular characterization of DCIS will offer additional,
perhaps more definitive, prognostic information and may provide the opportunity for
personalized therapeutic options for patients with DCIS.
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2. DCIS carcinogenesis
There is a continuum of non-obligate precursor lesions to IDC, consisting of flat epithelial atypia
(FEA), atypical ductal hyperplasia (ADH), and DCIS. Moreover, low-grade and high-grade DCIS
likely arise from two distinct evolutionary pathways. FEA is genetically related to ADH and is
likely a precursor to ADH, which, in turn, is the precursor to low-grade DCIS [4,15].

The pathophysiology of the malignant transformation from DCIS to IDC has been studied at the
molecular level. Comparative genomic hybridization studies of synchronous and metachronous
DCIS and IDC lesions have revealed a near identical pattern of genomic alterations, correlating
with tumor grade, supporting a molecular continuum between DCIS and IDC. Specifically, lowgrade lesions harbor frequent loss of 16q and 17p, while high grade lesions have complex
genomic alterations including 13q loss and high level amplifications of 17q12 and 11q13 [16].
The use of gene expression microarray technology has further refined our knowledge of DCIS
as a heterogeneous disease and has provided a new classification based on molecular
signatures. Ma et al discovered that unique gene expression signatures are associated with
different tumor grades, irrespective of tumor stage [17]. ADH, low-grade DCIS, and low-grade
IDC share a near identical gene expression profile consisting of genes associated with the
estrogen receptor phenotype, whereas both high-grade DCIS and high-grade IDC possess a
unique gene expression profile consisting of genes associated with mitotic activity and cell cycle
processes. Additionally, these authors identified a subset of genes with quantitative expression
levels that correlate with advanced tumor grade and with the transition from DCIS to IDC. This
suggests that the transcriptional program that drives cancer cells to an advanced tumor grade
may also confer invasiveness. Specifically, the gene ribonucleotide reductase M2 (RRM2) may
play a dual role in both supporting rapid cell proliferation and promoting invasive growth
behavior [17]. In the transition to invasive disease, low-grade DCIS lesions give rise to welldifferentiated IDC after a long latency period, and high-grade DCIS lesions give rise to poorly
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differentiated IDC after a relatively shorter time period [18]. Using a supervised classification,
Hannemann et al. identified a gene expression classifier of 35 genes, which differed between
DCIS and IDC and a panel of 43 genes which could further separate between well- and poorly
differentiated DCIS samples [19]. These findings were confirmed by Castro et al. who showed
that the tumor cells with the most divergent molecular features were from the pure DCIS cases,
providing further evidence that molecular changes in cells occur before morphological
alterations during the progression of IDC [20]. More recently, Lee and colleagues described a
74-gene profile which was able to correctly categorize 97% of all DCIS and 95% of all IBCs [21].
In addition, the performance of this signature was evaluated in cohorts from three similar
independent studies [21-24]. The discovery of distinct molecular subtypes in DCIS has further
validated these lesions as precursors of the different subtypes of invasive breast carcinomas.
Surprisingly, the tumor epithelial cells do not demonstrate significant qualitative gene expression
changes in the transition from in situ to invasive carcinoma. Instead the most dramatic
transcriptome changes take place prior to local invasion during the transition from normal
epithelium to DCIS [17,25]. In summary, the molecular data have shown that qualitatively, the
epithelial components of synchronous DCIS and IDC are remarkably similar.

3. Molecular pathology of DCIS
An important question regarding the molecular analysis of DCIS is to determine whether the
molecular subtypes identified in invasive cancers have the same significance in patients with
DCIS. All of the major molecular subtypes present in IBC (luminal A, luminal B, HER2+, and
basal-like) are seen in DCIS, although at different frequencies. Specifically, the frequency of the
luminal B and HER2+ phenotypes is significantly higher in DCIS than in IDC, and the frequency
of the luminal A phenotype is significantly higher in IDC than in DCIS [26]. Additionally, the
molecular subtypes correlate with grade. Low-grade DCIS is associated with ER positivity and
luminal phenotypes, while high-grade DCIS is associated with negative ER, positive HER2, and
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the basal-like phenotype [26]. The basal-like subtype seems to be associated with a higher risk
of local recurrence than are luminal subtypes, and may even have stronger and more consistent
associations than some of the conventional histopathological factors [10,27].

One of the interesting aspects of DCIS is that the expression of HER2 has been linked to
initiation and progression of breast cancer. Therefore, its frequent overexpression--commonly
seen in high grade DCIS with or without necrosis--suggests that HER2 plays a role in tumor
initiation and progression [28]. HER2 is a member of the type I receptor tyrosine kinase family,
which consists of four closely related family members: HER2, EGFR (HER1), HER3, and HER4.
The major role of HER2 is to serve as a co-receptor in the dimerization and activation of other
ERbB receptors. The amplification of the gene HER2 results in a 50 to 100 fold increase in the
number of surface HER2 receptors on cancer cells compared to normal mammary cells [29].
One of the possible mechanisms by which HER2 mediates breast carcinogenesis is through its
action on breast stem cells. HER2 promotes carcinogenesis by maintaining and increasing
cancer stem cells [30]. Interestingly, stem cells that overexpress HER2 are more sensitive to
trastuzumab and lapatinib [31]. In some studies, the expression of HER2/neu in DCIS has been
linked to recurrence following surgical excision without radiation therapy [7,32]. In our series of
DCIS patients treated with surgery alone, the expression of HER2 was associated with higher
recurrence rate and increased incidence of invasive recurrences in patients followed after many
years [7]. However, HER2 expression as an independent risk factor for recurrence remains
controversial. The expression of HER2 in DCIS and the existence of HER2-expressing stem
cells raise interesting issues regarding the possibility of using anti-HER2 compounds for
targeted therapy. These options are presently being investigated in clinical trials with the use of
anti-HER2 medications and anti-HER2 vaccines [33].

In addition to HER2 and steroid receptors, additional molecular markers may facilitate improved
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categorization of DCIS [34]. Other potential biomarkers that have been evaluated include
proliferation markers, cell cycle regulation and apoptotic markers, angiogenesis-related proteins,
cell adhesion molecules, epidermal growth factor receptor family receptors, extracellular matrix
proteins, and cyclooxygenase type-2 (COX-2) [35]. DCIS lesions with a low likelihood of
recurrence after surgical excision and of progression to invasive cancer are usually hormone
receptor positive, with normal levels of p53, lack of HER2 amplification, and low levels of Ki67
[18]. DCIS lesions with a high potential for recurrence after surgical excision and for progression
to invasive disease over a relatively short period of time are associated with HER2 amplification,
hormone negative receptor status, presence of TP53 mutation, and increased levels of Ki67
[18]. COX-2 has also been shown to be significantly up-regulated in DCIS with higher cell
proliferation rates, nuclear grade, ER negativity, and HER-2/neu positivity [18]. Berman et al
showed that DCIS showing overexpression of Ki67 and p16 by immunohistochemistry are more
likely to recur compared to tumors with low levels of expression [12].

4. Clinically validated prognostic markers for DCIS
The primary clinical dilemma in the management of DCIS patients relies on the fact that
traditional clinicopathologic features do not accurately predict in which patients the disease will
recur. Great advances have been made in the use of molecular profiling of invasive cancer for
risk assessment; however, its implementation in clinical practice for the study of DCIS is lagging
behind. Recently, a modified form of the Oncotype DX® recurrence score for IBC has been
developed for DCIS. This RT-PCR based assay is based on 12 genes from the Oncotype DX®
Invasive Recurrence Score. The algorithm uses 7 cancer-related genes (Ki67, STK15, Survivin,
CCNB1, MYBL2, PR and GSTM1) and 5 reference genes, to generate a score that quantifies
the likelihood of cumulative local recurrence (DCIS or invasive carcinoma) at 10 years and
predicts the risk of an invasive carcinoma local event at 10 years. The assay was initially
evaluated in a prospective study that included 327 of the 670 patients enrolled in the Eastern
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Cooperative Oncology Group (ECOG) 5149 clinical trial, who underwent surgery without
radiation. Approximately 30% of patients received tamoxifen. In the ECOG trial, patients were
divided in 2 cohorts: cohort 1 had low- or intermediate-grade DCIS measuring ≤2.5 cm; cohort 2
had high-grade DCIS measuring ≤1 cm with surgical margins ≥3 mm. Median age at surgery
was 60 years, and median tumor size was 6 mm. This study showed a 10-year risk for three
pre-specified DCIS risk groups of 10.6% (low), 26.7% (intermediate), and 25.9% (high). The
differences in the risks of developing local recurrence and invasive local recurrence between
patients with a lower DCIS Score and a higher DCIS Score were statistically significant and
clinically meaningful. The DCIS Score result was the strongest predictor of the risk of local
recurrence in the validation study. Among standard clinical and pathologic characteristics, only
tumor size and postmenopausal status were significant predictors of local recurrence, whereas
tumor grade and comedo necrosis were not (when the DCIS Score result was excluded from the
analysis). The power of this study was somewhat limited by the lack of tamoxifen randomization
in the ECOG trial, by the fact that gene selection and algorithm development were based partly
on studies of invasive carcinomas, and by the inclusion of only relatively few patients with
hormone receptors negative or HER2 positive DCIS [36].

A recent publication has demonstrated the value of Oncotype DX® DCIS score in a larger
population-based cohort of 718 patients diagnosed with DCIS treated with breast-conserving
surgery alone with validation of treatment and outcomes. Tissue blocks from 571 patients with
negative margins were available for the study. At a median follow-up of 9.6 years, 100 cases of
local recurrence were identified (57 invasive and 44 DCIS). Using the Oncotype DX® DCIS
score retrospectively, the 10-year risk of local recurrence was estimated at 12.7% for low-risk
patients, 27.8% for intermediate-risk patients, and 33% for high-risk patients. The score also
predicted invasive recurrence and DCIS recurrence. The outcomes of this cohort were
remarkably similar to the ECOG’s study one. Limitations of the study included the fact that
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patients were not randomized, and the use of and compliance with tamoxifen treatment was
limited [37]. Additionally, it is often difficult to differentiate between true recurrence and the
appearance of a second primary carcinoma, which is a limitation to all studies involving breast
cancer recurrence. Lastly, for women with low DCIS scores, the 10-year local recurrence rates
approached 11% and 13% in these two major studies, rates which many clinicians deem not low
enough to justify omission of radiation therapy. Therefore, this assay has not yet been
universally implemented into clinical practice.

In light of the numerous biomarkers that are being investigated for their role in the pathogenesis
of DCIS, it is important to remember the current recommendations for routine practice of
pathology. ER is currently the only biomarker validated for routine clinical practice in DCIS, and
the National Comprehensive Cancer Network practice guidelines include determination of ER
status as part of the work-up of DCIS [2,38]. The majority (75-80%) of DCIS cases are ER
positive. This information is used to determine if a patient with DCIS will benefit from hormonal
therapy. However, the Update Committee of the American Society of Clinical Oncology
concluded that current data are insufficient to make a general recommendation for the use of
ER status of DCIS to make decisions about tamoxifen treatment [39]. Furthermore, even
though PR is often ordered in conjunction with ER, there is almost no data on the association of
PR status and DCIS. Thus, a surgical pathologist should decide which markers to routinely
perform upon consultation with the clinicians who will use this information.

In our practice, all cases of DCIS are tested for ER, PR, HER2 and Ki67 expression. While we
are not advocating this as universal routine practice, we have observed that the expression of
these markers can sometimes affect the treatment decisions of clinicians at our institution.
Additionally, building a cohort of cases tested with this panel of markers will allow us to observe
their patterns of expression and investigate how they may underlie biologic differences in DCIS
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lesions. Other biomarkers currently under investigation could potentially become part of routine
ordering practice, should they demonstrate prognostic or therapeutic significance. Available
molecular tests such as Oncotype DX® also have the potential to become useful for predicting
outcome in certain patients, especially since comprehensive histopathologic analysis alone
does not seem to be sufficient for evaluating recurrence risk. Certainly, the impact of the costs
of molecular tests and their application to a wide spectrum of patients with DCIS need to be
analyzed in order to maximize their effect on patient management. We envision a future where
we can better stratify patients with DCIS using a combination of pathologic examination,
immunohistochemical studies and molecular analysis.

5. The transition from DCIS to invasive carcinoma
One of the areas of interest in recent years in patients with DCIS has been the study of the cells'
ability to invade, grow in the stroma, and acquire metastatic potential. All of these steps are
crucial, since preventing the tumor cells from becoming invasive is one of the major goals in the
treatment of DCIS. Myoepithelial cells, stromal cells, vascular supply, and cell-mediated immune
mechanisms all play a role in the transition from DCIS to invasive cancer [Figure 1].
The key morphological distinction between DCIS and IDC is the preservation of the
myoepithelial cell layer in DCIS; the lack of myoepithelial cells is considered one of the
hallmarks of invasive carcinoma [40].

Myoepithelial cells are known to be biologically different in normal and neoplastic breast tissue.
In DCIS, they function as tumor suppressors, inhibitors of the invasive properties of the
epithelial cells and angiogenesis [40,41]. Loss of myoepithelial cells is routinely tested for with
immunohistochemical markers such as p63, calponin, smooth muscle actin, CD10, cytokeratin
(CK) 5/6, S-100 protein, and smooth muscle myosin heavy chain (SMMHC). Heterogeneity in
the staining patterns can be seen with these markers, which has prompted pathologists to use
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more than one marker to exclude invasive carcinoma. Altered expression of these markers has
been observed in the myoepithelial cells of DCIS lesions. Hilson et al. were the first to report
reduced staining intensity of DCIS-associated myoepithelial cells with various myoepithelial cell
markers, lending support to the idea that these myoepithelial cells are phenotypically abnormal
[42]. These authors also found that SMMHC, CD10 and CK 5/6 have lower sensitivity for DCISassociated myoepithelial cells than do SMA, p63 and calponin [42]. At our institution, we used
two of the most common markers, p63 and calponin, in a large series of DCIS cases which
revealed heterogeneous expression of these myoepithelial markers [Figure 2]. In this
retrospective experience, we saw a marked decreased in the expression of these markers in
high grade DCIS with necrosis, pleomorphic lobular carcinoma in situ, and in DCIS with
associated invasive cancers. In contrast to these tumors, classic lobular carcinoma in situ and
low grade DCIS showed strong and continuous expression of these two markers. This study
showed significant heterogeneity according to the lesions and to the markers applied and
emphasizes the importance of using more than one antibody.

The reasons for the immunohistochemical heterogeneity and for the decreased and absence of
myoepithelial cells in the pre-invasive phase are not currently known. Two theories have been
proposed regarding the mechanism by which myoepithelial cells are lost. One hypothesis
suggests that genetic changes in tumor epithelial cells may eventually select for a clone with
invasive properties that can escape from the duct, spread into the stroma, and subsequently
expand [43]. However, countering this hypothesis are studies demonstrating that the tumor
epithelial cells do not undergo significant gene expression changes in the transition from DCIS
to IDC [17]. The second hypothesis suggests that phenotypic changes in DCIS myoepithelial
cells, together with accumulation of stromal inflammatory cells and myofibroblasts, lead to
breakdown of the ducts and release of the tumor epithelial cells into the surrounding stroma
[41,43]. Many of the genes that are specific for normal myoepithelial cells, such as CTK14,
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CTK17, OXTR and EGFR, have been shown to be absent or dramatically downregulated in the
myoepithelial cells of DCIS lesions [43]. Not only do the DCIS myoepithelial cells lack their
normal tumor suppressive abilities, they may instead possess a reversed function, with the
ability to promote tumor progression [44].

The surprising lack of genomic evolution between DCIS and IDC has led researchers to focus
on the potential role of the stromal microenvironment in mediating the transition to invasion. It is
known that the tumor-associated stromal cells secrete factors such as vascular endothelial
growth factor, IL-6, and IL-8, which promote angiogenesis and breast cancer progression [45].
In contrast to the tumor epithelial cells, the tumor-associated stromal cells demonstrate distinct
gene expression changes during the transition from in situ to invasive carcinoma. Ma et al.
showed that in stromal cells, the transition to invasive growth is accompanied by increased
expression of several matrix metalloproteases including MMP2, MMP11, and MMP14 [46].
Interestingly, the vast majority (>90%) of the stromal gene expression changes observed
between normal tissue and IDC occur early at the normal to DCIS transition [47]. Allinen et al.
conducted an elegant comprehensive molecular characterization of each cell type (epithelial,
myoepithelial and various stromal cells) composing normal breast tissue, in situ and invasive
carcinoma to better understand the role of these cells in breast carcinogenesis [48]. The authors
found that extensive gene expression changes occur in all cell types during cancer progression,
with the most consistent and dramatic changes affecting myoepithelial cells. Surprisingly,
genetic clonal alterations were detected only in cancer epithelial cells [48]. These findings were
confirmed by another independent study that showed no evidence of clonal somatic genetic
alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas [49].
The contribution of both the epithelial and stromal compartments to the clinically important
scenario of progression from DCIS to IDC has been shown by another independent study [50].
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Muggerud et al. identified a set of genes independent of grade, ER-status, and HER2-status
which allowed them to classify a subgroup of high-grade DCIS with a more active stroma and
epithelial-mesenchymal transition (EMT) markers, molecularly similar to “more advanced”
lesions such as invasive carcinoma [51]. Sharma et al also shed more light on the interaction
between tumor cells and their surrounding stroma in model systems. These authors identified
two distinct stromal signatures derived from a macrophage response and a fibroblastic response
that were present in subsets of invasive and in-situ carcinomas [52]. Of interest, the
macrophage response signature was associated with a more aggressive phenotype, higher
grade DCIS and cases which were ER and PR negative, whereas the fibroblast signature was
not associated with any clinicopathologic features in DCIS. This study suggests the role of the
microenvironment as a potential “driver” of disease behavior [52]. Gene expression profiling has
revealed that substantial changes occur during progression from DCIS to IBC in various cell
types of the tumor stromal microenvironment; however, no clonal genetic aberrations have been
detected in the myoepithelial cells and fibroblasts surrounding DCIS or IBC [44,46].

Further support to the increasing evidence that changes in the cellular microenvironment
contribute to tumorigenesis has been provided by Hu et al. The authors analyzed epithelial,
myoepithelial cells, and fibroblasts from normal, in situ and invasive breast cancers, through
methylation-specific digital karyotyping and found consistent differences in DNA methylation
between normal and neoplastic breast tissue in each cell type analyzed [53]. Recently, Fleischer
and colleagues also investigated methylation patterns during progression of breast cancer [54].
Genome wide DNA methylation analysis was carried out in a total of 285 fresh frozen tissue
samples, including 46 normal breast tissue samples from healthy women, 22 pure DCIS, 31
mixed DCIS-IBC and 186 IBC. The authors concluded that most of the aberrations in the
epigenetic profile were observed already in the pre-invasive DCIS stage, while the changes
between DCIS and IBC were comparably modest [54].
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6. The role of methylation analysis in DCIS
DNA methylation is an epigenetic modification of the human genome that is implicated in
cancer. The altered DNA methylation patterns found in breast cancer cells include both
hypomethylation and hypermethylation of specific gene regions. In particular, promoter
hypermethylation has been implicated as an early event in breast carcinogenesis [55]. The role
of methylation in DCIS and breast cancer progression has been investigated in numerous
studies that used different methodologies, analyzed different gene sets, and examined different
promoter regions [56,57].

In brief, methylation studies have showed that the number of methylated genes increased
stepwise from normal breast to DCIS, whereas IDC did not differ from DCIS. These findings
suggest that most of the dramatic epigenetic changes take place during the transition from
normal epithelium to DCIS and that aberrant methylation may not contribute to the development
of invasion but rather play an important role in early breast carcinogenesis [58-60]. Recent
studies, some of which have used a genome-wide methylation screen approach have described
a small set of genes such as APC, CACNA1A, CDH1, FOXC1, HOXA10, MGMT, SFPR1,
TFAP2A, and TWIST1 that exhibit differences in either frequency or density of methylation
between DCIS and invasive carcinoma [61-70]. In view of these findings, the analysis of such a
gene panel through quantitative methylation might represent a tool for predicting disease
progression. These data have been confirmed by Fleischer et al. who recently reported the DNA
methylation profiles of a breast cancer progression series, including normal breast tissue, DCIS,
invasive carcinoma, and mixed lesions [54]. In agreement with previous studies, most of the
aberrations in the epigenetic profile were observed already in the pre-invasive stage. Of note
the authors also described a signature comprising DNA methylation levels of 18 CpGs that was
prognostic for breast cancer patients with invasive tumors as well as for patients with DCIS and
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mixed lesions of DCIS and invasive breast carcinoma [54].

7. MicroRNAs and DCIS
MicroRNAs (miRNAs) are a class of small noncoding RNAs that control gene expression by
targeting mRNAs and triggering either translation repression or RNA degradation [71]. miRNAs
have been shown to control several cellular processes, including metabolism, stem cell division,
cell growth and differentiation and apoptosis [72-76]. The effect of miRNAs on mRNA
expression and its contribution to the pathogenesis of many diseases, including mammary
carcinogenesis has been elucidated in the last decade [77-83]. In a seminal study, Iorio et al.
demonstrated aberrant expression of miRNA, notably miR-125b, miR-145, miR-21, and miR155, in human breast cancer. Furthermore, the authors identified miRNAs whose expression
was correlated with specific breast cancer biopathologic features, such as estrogen and
progesterone receptor expression, tumor stage, vascular invasion, or proliferation index [84].
Hannafon et al. performed an integrated analysis of miRNA and mRNA expression in paired
samples of histologically normal and pre-invasive breast cancer and found that major miRNA
expression changes occur at the transition from normal to DCIS epithelium [85]. The authors
further demonstrated, by modulating the expression of several miRNA, that the expression of
their predicted target genes is affected. This work implicated the loss of the tumor suppressor
miR-125b and the gain of the oncogenic miRNA miR-182 and miR-183 as major contributors to
early breast cancer development [85]. Farazi et al. profiled miRNAs from normal breast tissues,
DCIS, invasive breast carcinomas, and 6 cell lines by Solexa sequencing and showed that
normal breast samples were separated from most noninvasive DCIS and invasive carcinomas
by increased miR-21 (the most abundant miRNA in carcinomas) and multiple decreased miRNA
families, with most miRNA changes apparent already in the noninvasive carcinomas [86]. In
essence, the study confirmed prior findings and supported the view that most miRNA changes
in IDC were already apparent in DCIS samples [86]. Similarly Volinia et al. created miRNA
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profiles for normal breast, DCIS, and invasive carcinomas to study the global changes of the
miRNA repertoire along the transition defining breast carcinoma progression [87]. The miRNA
profile established for the normal breast to DCIS transition was largely maintained in the in situ
to IDC progression. Nevertheless, a nine-miRNA signature was identified that differentiated
invasive from in situ carcinoma along with five miRNAs associated with time to metastasis and
overall survival in IDC patients. Of clinical interest miR-210, which resulted to be regulated
during breast cancer progression, was also a component of the two prognostic signatures [87].

8. Next-generation sequencing
Next-generation sequencing (NGS) technologies are revolutionizing our ability to characterize
breast cancer at the genomic, transcriptomic and epigenetic levels. Unlike microarrays, that
have been the technology of choice in most gene expression studies, NGS does not depend on
prior sequence information; hence, the identification and quantification of gene expression is
unbiased. Moreover NGS offers unprecedented depth of analysis of gene expression and is not
affected by potential cross hybridization [88-91]. NGS has been already exploited in DCIS with
the production of massive quantity of data, and this is just the beginning. Kaur et al. used next
generation sequencing to identify the transcriptional fingerprint of three DCIS models at the
whole genome level [92]. This remarkable study revealed significant increases in ALDH5A1
(enzyme of glutamate metabolism) expression in the DCIS models and demonstrated that two
independent drugs (disulfiram and valproic acid) reduce net proliferation in DCIS by inhibiting
ALDH5A1 activity [92]. In 2012 Banerij et al. performed whole-exome sequencing of 103
primary, treatment-naive breast carcinomas including 9 cases of DCIS. Although the results
pertinent to the small subset of DCIS samples were not separately elucidated from the entire set
of 103 cancers, the overall data set exhibited recurrent somatic mutations in 5 known genes-PIK3CA, TP53, AKT1, GATA3, and MAP3K1--and discovered new mutations in the CBFB
transcription factor gene along with deletions of its partner RUNX1 [93].
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9. Conclusions
With the increased frequency of breast cancers detected at the non-invasive stage, pathologists
play an increasingly significant role. This role is not limited to the diagnosis (benign versus
malignant) but to providing important information to guide treatment decisions in patients with
DCIS and to determine the risk of recurrence and progression to invasive carcinoma. DCIS is a
heterogeneous lesion which can demonstrate different morphological patterns and express
combinations of immunohistochemical and molecular markers. A better understanding of the
molecular events of the lesions preceding DCIS and of the DCIS itself will lead to better
methods of prevention and treatment options for these patients. The biological changes in the
various cellular components of DCIS, including the tumor epithelial cells, myoepithelial cells,
and stromal cells, may hold the key to whether or not a given lesion will progress to invasive
carcinoma.

The progression from in situ to invasive breast cancer is a very complex biological
phenomenon. The cells in DCIS lesions that do progress to invasive cancer likely already harbor
molecular alterations that render them prone to progress and become invasive. Therefore,
defining DCIS on a molecular basis may be a more accurate way of accounting for the frequent
heterogeneity of these lesions and how this manifests as differences in patient outcome and
response to therapy. Testing DCIS lesions with molecular markers may better predict the risk of
disease progression. Overcoming tumor heterogeneity will be a major challenge to identify the
genes driving the progression of DCIS. In the future, the classification of DCIS will include
histologic, immunohistochemical, and molecular markers, in order to tailor a patient’s
management to the biological nature and malignant potential of their individual DCIS lesions.
Newer treatment modalities in clinical trials such as anti-HER2 compounds, vaccines, inhibitors
of angiogenesis, and growth factors await the results to evaluate their implementation in clinical
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practice.
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Figure captions:
Figure 1: The progression to IDC.
The progression from normal breast epithelium to DCIS and IDC is characterized by alterations
in the epithelial cells, myoepithelial cells, stromal cells and vascular supply. In the transition
from normal epithelium to DCIS, epithelial cells undergo changes in miRNA expression and the
methylation patterns of various genes; they do not demonstrate significant qualitative gene
expression changes in the transition from in situ to invasive carcinoma. Myoepithelial cells
undergo dramatic downregulation of many genes, causing them to lose their normal tumor
suppressive abilities and allowing the epithelial cells to invade beyond the basement membrane.
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Loss of the myoepithelial cell layer is the hallmark of IDC. Angiogenesis, stimulated by local
tissue hypoxia and factors elaborated by tumor-associated fibroblasts and macrophages,
supports the growth of the expanding tumor.
Figure 2: Heterogeneity of myoepithelial marker expression.
Heterogeneity of expression of myoepithelial markers as detected by double
immunohistochemical staining for p63 and calponin, illustrating decreased calponin staining in
intermediate grade carcinoma (A); strong calponin staining in apocrine DCIS (B); marked
decreased in both markers in high grade DCIS with early invasion (C), and heterogeneity in
staining with decreased staining in both markers in one duct with high grade DCIS (D).
(Immunohistochemistry, x400)

